The debut of troglitazone, a potent insulin-sensitizing agent, marked a significant chapter in the management of type 2 diabetes. However, its discontinuation from the market due to substantial hepatotoxicity spurred extensive investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering analogous mech